Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Not Recruiting

Open to: ALL

Age: 18.0 - 74.0

Medical Conditions

Psoriasis
Body Weight


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study investigates if an adjusted brodalumab dosage regimen will give improved efficacy in psoriasis in patients with a body weight of over 120 kg. The increased dosage regimen will be compared to the standard brodalumab treatment plus placebo.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2022 Aug 2025

INTERVENTIONAL

Intervention Type : BIOLOGICAL
Intervention Description : Brodalumab is an anti-IL-17 receptor antibody, which blocks the inflammatory effects of IL-17 in the skin.

Intervention Arm Group : Brodalumab 210 mg + brodalumab 70 mg add-on* (adjusted brodalumab dosing regimen);Brodalumab 210 mg + placebo add-on* (standard brodalumab treatment);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • LEO Pharma Investigational Site
    Chorley
    PR7 7NA
  • LEO Pharma Investigational Site
    Corby
    NN17 2UR
  • LEO Pharma Investigational Site
    Corby
    NN18 9EZ
  • LEO Pharma Investigational Site
    Coventry
    CV3 4FJ
  • LEO Pharma Investigational Site
    Liverpool
    L22 0LG
  • LEO Pharma Investigational Site
    London
    BR5 3QG
  • LEO Pharma Investigational Site
    London
    E1 2ES
  • LEO Pharma Investigational Site
    Northwood
    HA6 2RN
  • LEO Pharma Investigational Site
    Shipley
    BD18 35A


The study is sponsored by LEO Pharma




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT04306315
Last updated 22 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.